Ronald E. Cape

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.

Caprion Pharmaceuticals, Inc. discovered and developed pharmaceutical products. It offered a proprietary therapeutic pipeline in oncology and infectious diseases. Caprion Pharmaceuticals proteomics discovery technologies used to enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly enhance clinical development productivity and decision making. The company was founded in 1998 and was headquartered in Montreal, Canada.

Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA.

San Francisco Opera Association owns and operates opera theater. It offers an array of training programs and performance opportunities for young artists under the support of the San Francisco Opera Center and the Merola Opera Program. The company was founded by Gaetano Merola in 1923 and is headquartered in San Francisco, CA.

Based in Menlo Park, California, Earlybird LLC is a subsidiary of venture capital firm Earlybird Venture Capital GmbH & CoKG.

BYTC Corp. manufactures pharmaceutical products. It also engages in the development of technology for the production of monoclonal antibodies for biodefense. The company was founded by Stuart W. Dorsey in 1993 and is headquartered in San Francisco, CA.

Follica, Inc. develops therapies for hair follicle disorders. The firm provides an out-patient therapy coupled with an at-home system for the treatment of androgenetic alopecia (hair loss) and medical device development fields to develop and commercialize its product platform. The company was founded by Rox R. Anderson, George Cotsarelis, Vera Price, Daphne Zohar, David Steinberg, and Bernat Olle in 2006 and is headquartered in Boston, MA.